Palatin Technologies, Inc

Palatin Technologies Inc. is a U.S.-based biopharmaceutical company developing receptor-specific medicines built around the melanocortin receptor system. Its pipeline includes peptide and small-molecule drug candidates aimed at obesity, metabolic disorders, inflammatory conditions, and other diseases with unmet medical need.

−100,0 %

0.36

0.36

— Palatin Technologies, Inc
%
MC4R obesity and metabolic programs40% Drug candidates targeting melanocortin-4 receptors for obesity, hypothalamic obesity, and related disorders.
MC1R anti-inflammatory programs25% Peptide therapeutics designed to modulate inflammation and immune response through MC1R activity.
Multi-receptor melanocortin programs15% Programs using peptides active at more than one melanocortin receptor for broader therapeutic effects.
Small-molecule MCR programs15% Oral small-molecule melanocortin receptor agonists under development for easier administration.
Commercialization and licensing5% Partnering, licensing, and collaboration arrangements used to advance and monetize assets.

Palatin’s direct customers are primarily pharmaceutical and biopharmaceutical partners, since the company’s model is to...

  • Pharmaceutical licensing partnersprimary

    Large pharma or specialty pharma companies that may license or commercialize Palatin assets.

  • Biopharmaceutical collaboratorsprimary

    Development partners that help fund, advance, or co-develop pipeline programs.

  • Patients and prescribers in obesityprimary

    Future end users of MC4R-based therapies for obesity and related metabolic disorders.

  • Patients with inflammatory diseasessecondary

    Potential users of MC1R-based anti-inflammatory therapies if approved.

  • Research and manufacturing vendorssecondary

    CROs, clinical sites, and manufacturers that support preclinical and clinical development.

Palatin is headquartered in the United States and conducts development and partnering activities from its U.S. base...

  • •Headquartered and operated in the United States
  • •Clinical and regulatory work is primarily U.S.-based
  • •Commercial strategy contemplates U.S. and international partners
  • •Future market reach depends on partner geography and approvals

Palatin’s strategy is to advance melanocortin-based drug candidates through preclinical and clinical development and...

01
Advance MC4R obesity programsmedium-term

These programs target a large market and are central to the company’s pipeline value.

02
Develop MC1R anti-inflammatory assetsmedium-term

MC1R programs diversify the pipeline and address diseases with unmet medical need.

03
Secure collaboration and licensing partnersshort-term

Partnering is the main route to commercialization and can provide non-dilutive support.

04
Raise capital and manage burnshort-term

Clinical development requires funding before any product revenue can be sustained.

Palatin faces the typical risks of an early-stage biopharmaceutical company: clinical failure, regulatory delay, and...

high

Insufficient funding to complete development programs

The company must finance clinical trials and regulatory work before product sales can scale.

Scope
Pipeline development and corporate operations
Materiality
high
high

Clinical and regulatory failure

Drug candidates may not demonstrate safety, efficacy, or approvability in humans.

Scope
MC1R and MC4R programs
Materiality
high
high

Intense competition in obesity therapeutics

Large pharma and biotech companies have greater resources and established products.

Scope
MC4R obesity programs
Materiality
high
medium

Dependence on third-party collaborators and contractors

CROs, manufacturers, and partners perform much of the work needed to advance assets.

Scope
Preclinical studies, clinical trials, commercialization
Materiality
high
medium

Intellectual property and trade secret leakage

Proprietary receptor-modulating technologies may be copied or independently developed.

Scope
Pipeline technology and know-how
Materiality
medium
Accrued research and development expenses
Can shift quarterly operating expense and liabilities
Revenue recognition for product sales and collaborations
Can create volatility in reported revenue
Stock-based compensation
Can materially affect operating expenses
Going-concern assessment and liquidity disclosures
Important for solvency and capital structure analysis

PALATIN TECHNOLOGIES INC

PTN · Pharmaceutical Preparations

Palantir Technologies Inc.

PLTR · Services-Prepackaged Software

Palladyne AI Corp.

PDYN · Services-Prepackaged Software

ALIGN TECHNOLOGY INC

ALGN · Orthopedic, Prosthetic & Surgical Appliances & Supplies

Voip-pal.com Inc

VPLM · Telephone & Telegraph Apparatus

DYADIC INTERNATIONAL INC

DYAI · Biological Products, (No Diagnostic Substances)

: 29.4.2026